Awardee OrganizationST. JUDE CHILDREN'S RESEARCH HOSPITAL
Description
Abstract Text
The long-term goal of this research is to understand the pathogenesis of
viral diseases at the molecular level. Studies in the principal
investigator's laboratory identified the structural features of avian
influenza virus hemagglutinin (HA) that determine its cleavage and
established that a single point mutation in the HA could alter virulence of
influenza viruses. Knowledge gained from these studies has made it
possible to pursue four specific aims directly related to the molecular
pathogenesis of human influenza. 1. Elucidation of the structural features
required for HA cleavage of mammalian Influenza viruses. The structural
features required for HA cleavage in mammalian influenza viruses will be
identified by selection of HA mutants and by in vitro mutagenesis performed
on the cloned HA genes. This information should provide the molecular
basis for the enzyme-substrate interaction underlying HA cleavage. 2.
Determination of the intracellular location of HA cleavage. The site of HA
cleavage within cells will be sought by use of markers of protein transport
and monoclonal or polyclonal antibodies specific for uncleaved or cleaved
HA. These studies should disclose the cellular organelle where the
cleavage enzyme resides. 3. Purification and characterization of the
cleavage enzyme for HAs with multiple basic amino acids at the cleavage
site. Isolation and characterization of the cleavage enzyme will be
critical in studies to establish the basis of cleavage activation of the
HA. 4. Determination of the tissue distribution of the cleavage enzyme in
mice. Genetic and immunological probes will be used to directly establish
the relative amounts of cleavage enzyme in different tissue sites, as a
means of proposed studies should lead to a better understanding of the
pathogenesis of influenza by establishing the molecular basis of cleavage
activation of the HA. Because there are many viral glycoproteins with
multiple basic amino acids at the cleavage site, the pathogenetic mechanism
identified in this proposal may also apply to other viral diseases. It may
be possible to use the findings of this research to develop inhibitors of
the HA cleavage enzyme, which could lead to a suitable chemotherapeutic
approach to the control of influenza due to highly virulent viruses.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
chemical binding chemical cleavage enzyme inhibitors enzyme substrate fluorescence microscopy gel electrophoresis glycoproteins human tissue immunoelectron microscopy immunoprecipitation in situ hybridization influenza laboratory mouse laboratory rabbit microorganism disease chemotherapy microorganism hemagglutinin molecular cloning molecular pathology nucleic acid probes nucleic acid sequence pathologic process point mutation protein purification protein sequence protein structure site directed mutagenesis tissue /cell culture virus antigen virus cytopathogenic effect virus diseases virus protein virus replication
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
067717892
UEI
JL4JHE9SDRR3
Project Start Date
01-July-1990
Project End Date
30-April-1995
Budget Start Date
01-May-1994
Budget End Date
30-April-1995
Project Funding Information for 1994
Total Funding
$172,909
Direct Costs
$118,240
Indirect Costs
$54,669
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Allergy and Infectious Diseases
$172,909
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI029599-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI029599-05
Patents
No Patents information available for 5R01AI029599-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI029599-05
Clinical Studies
No Clinical Studies information available for 5R01AI029599-05
News and More
Related News Releases
No news release information available for 5R01AI029599-05
History
No Historical information available for 5R01AI029599-05
Similar Projects
No Similar Projects information available for 5R01AI029599-05